Recombinant multi-species CDK8/19/CDK19 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine CDK8/19/CDK19 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene encodes a protein that is one of the components of the Mediator co-activator complex. The Mediator complex is a multi-protein complex required for transcriptional activation by DNA binding transcription factors of genes transcribed by RNA polymerase II. The protein encoded by this gene is similar to cyclin-dependent kinase 8 which can also be a component of the Mediator complex. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2014]
The Alternative Names of target: 19,2700084L06Rik,CDC2-related protein kinase 6,CDC2L6,CDK11,CDK19,CDK8,Cdc2l6,Cdk11,Cdk19,Cell division cycle 2-like protein kinase 6,Cell division protein kinase 19,Cyclin-dependent kinase 11,Cyclin-dependent kinase 19,DEE87,Death-preventing kinase,EIEE87,bA346C16.3,mKIAA1028

Target products collectionGo to CDK8/19/CDK19 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-T98034-Ag-1/ GM-Tg-hg-T98034-Ag-2 Human CDK8/19/CDK19 protein Human
GM-Tg-rg-T98034-Ag-1/ GM-Tg-rg-T98034-Ag-2 Rat CDK8/19/CDK19 protein Rat
GM-Tg-mg-T98034-Ag-1/ GM-Tg-mg-T98034-Ag-2 Mouse CDK8/19/CDK19 protein Mouse
GM-Tg-cynog-T98034-Ag-1/ GM-Tg-cynog-T98034-Ag-2 Cynomolgus/Rhesus macaque CDK8/19/CDK19 protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-T98034-Ag-1/ GM-Tg-felg-T98034-Ag-2 Feline CDK8/19/CDK19 protein Feline
GM-Tg-cang-T98034-Ag-1/ GM-Tg-cang-T98034-Ag-2 Canine CDK8/19/CDK19 protein Canine
GM-Tg-bovg-T98034-Ag-1/ GM-Tg-bovg-T98034-Ag-2 Bovine CDK8/19/CDK19 protein Bovine
GM-Tg-equg-T98034-Ag-1/ GM-Tg-equg-T98034-Ag-2 Equine CDK8/19/CDK19 protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-T98034-Ag-1/ GM-Tg-hg-T98034-Ag-2; GM-Tg-rg-T98034-Ag-1/ GM-Tg-rg-T98034-Ag-2;
GM-Tg-mg-T98034-Ag-1/ GM-Tg-mg-T98034-Ag-2; GM-Tg-cynog-T98034-Ag-1/ GM-Tg-cynog-T98034-Ag-2;
GM-Tg-felg-T98034-Ag-1/ GM-Tg-felg-T98034-Ag-2; GM-Tg-cang-T98034-Ag-1/ GM-Tg-cang-T98034-Ag-2;
GM-Tg-bovg-T98034-Ag-1/ GM-Tg-bovg-T98034-Ag-2; GM-Tg-equg-T98034-Ag-1/ GM-Tg-equg-T98034-Ag-2
Products Name CDK8/19/CDK19 protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name CDK8/19/CDK19
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine CDK8/19/CDK19 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.